

Hamid Badali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5272524/publications.pdf>

Version: 2024-02-01

186
papers

34,734
citations

50566

48
h-index

4741

175
g-index

193
all docs

193
docs citations

193
times ranked

53721
citing authors

#	ARTICLE	IF	CITATIONS
1	South Asian (Clade I) <i>Candida auris</i> meningitis in a paediatric patient in Iran with a review of the literature. <i>Mycoses</i> , 2022, 65, 134-139.	1.8	20
2	A Chronic Autochthonous Fifth Clade Case of <i>Candida auris</i> Otomycosis in Iran. <i>Mycopathologia</i> , 2022, 187, 121-127.	1.3	18
3	Evaluating a semi-nested PCR to support histopathology reports of fungal rhinosinusitis in formalin-fixed paraffin-embedded tissue samples. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24209.	0.9	5
4	Species Distribution and Antifungal Susceptibilities of <i>Aspergillus</i> Section <i>Fumigati</i> Isolates in Clinical Samples from the United States. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0028022.	1.8	18
5	<i>Eumycetoma</i> causative agents are inhibited in vitro by luliconazole, lanconazole and ravuconazole. <i>Mycoses</i> , 2022, 65, 650-655.	1.8	10
6	Global prevalence and subgroup analyses of coronavirus disease (COVID-19) associated <i>Candida auris</i> infections (CACa): A systematic review and meta-analysis. <i>Mycoses</i> , 2022, 65, 683-703.	1.8	37
7	In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant <i>Fusarium</i> Strains. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 709.	1.5	4
8	Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of <i>Aspergillus</i> Species. <i>Journal De Mycologie Medicale</i> , 2022, 32, 101310.	0.7	13
9	Multidrug-resistant <i>Trichophyton mentagrophytes</i> genotype VIII in an Iranian family with generalized dermatophytosis: report of four cases and review of literature. <i>International Journal of Dermatology</i> , 2021, 60, 686-692.	0.5	44
10	Overexpression of Efflux Pump Genes is an Alternative Mechanism in Voriconazole Resistant <i>Aspergillus fumigatus</i> isolates Without Relative Mutations in CYP5A. <i>Infectious Disorders - Drug Targets</i> , 2021, 20, 860-866.	0.4	2
11	Pulmonary infection secondary to <i>Blastobotrys raffinosifermentans</i> in a cystic fibrosis patient: Review of the literature. <i>Mycoses</i> , 2021, 64, 616-623.	1.8	2
12	The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. <i>Mycoses</i> , 2021, 64, 798-808.	1.8	149
13	Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis. <i>Mycopathologia</i> , 2021, 186, 245-257.	1.3	19
14	Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran. <i>Mycoses</i> , 2021, 64, 780-787.	1.8	12
15	In vitro activity of olorofim against clinical isolates of the <i>Fusarium oxysporum</i> and <i>Fusarium solani</i> species complexes. <i>Mycoses</i> , 2021, 64, 748-752.	1.8	19
16	First Fluconazole-resistant <i>Candida auris</i> isolated from fungal otitis in Iran. <i>Current Medical Mycology</i> , 2021, 7, 51-54.	0.8	10
17	Molecular typing of clinical and environmental <i>Aspergillus fumigatus</i> isolates from Iran using microsatellites. <i>Current Medical Mycology</i> , 2021, 7, 25-30.	0.8	1
18	Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the <i>Fusarium oxysporum</i> and <i>Fusarium solani</i> Species Complexes. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	17

#	ARTICLE	IF	CITATIONS
19	Fatal necrotising cutaneous mucormycosis due to novel <i>Saksenaea</i> species: a case study. <i>Journal of Wound Care</i> , 2021, 30, 465-468.	0.5	5
20	MALDI-TOF MS characterisation, genetic diversity and antifungal susceptibility of <i>Trichosporon</i> species from Iranian clinical samples. <i>Mycoses</i> , 2021, 64, 918-925.	1.8	7
21	Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0123021.	1.8	32
22	MixInYeast: A Multicenter Study on Mixed Yeast Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 13.	1.5	14
23	Isolation and molecular characterization of clinical and environmental dematiaceous fungi and relatives from Iran. <i>Current Medical Mycology</i> , 2021, 7, 1-8.	0.8	5
24	In vitro synergy of echinocandins with triazoles against fluconazole-resistant <i>Candida parapsilosis</i> complex isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 331-334.	0.9	2
25	Interactions between immune response to fungal infection and microRNAs: The pioneer tuners. <i>Mycoses</i> , 2020, 63, 4-20.	1.8	10
26	A systematic review of <i>Toxoplasma gondii</i> genotypes and feline: Geographical distribution trends. <i>Transboundary and Emerging Diseases</i> , 2020, 67, 46-64.	1.3	23
27	Clonal Expansion of Environmental Triazole Resistant <i>Aspergillus fumigatus</i> in Iran. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 199.	1.5	16
28	Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against <i>Aspergillus</i> and <i>Candida</i> isolates. <i>Journal De Mycologie Medicale</i> , 2020, 30, 101014.	0.7	33
29	Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope™ Global Registry for Emerging Fungal Infections. <i>Journal of Infection</i> , 2020, 81, 802-815.	1.7	20
30	Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran. <i>Mycopathologia</i> , 2020, 185, 607-611.	1.3	124
31	The urgent need for integrated science to fight COVID-19 pandemic and beyond. <i>Journal of Translational Medicine</i> , 2020, 18, 205.	1.8	128
32	Antifungal Activity of a Novel Triazole, Efinaconazole and Nine Comparators against 354 Molecularly Identified <i>Aspergillus</i> Isolates. <i>Mycopathologia</i> , 2020, 185, 357-365.	1.3	6
33	First azole-resistant <i>Aspergillus fumigatus</i> isolates with the environmental TR ₄₆ /Y121F/T289A mutation in Iran. <i>Mycoses</i> , 2020, 63, 430-436.	1.8	29
34	Epidemiological features of nosocomial candidaemia in neonates, infants and children: A multicentre study in Iran. <i>Mycoses</i> , 2020, 63, 382-394.	1.8	34
35	Rapid and Low-Cost Culture-Based Method for Diagnosis of Mucormycosis Using a Mouse Model. <i>Frontiers in Microbiology</i> , 2020, 11, 440.	1.5	6
36	Hazard of agricultural triazole fungicide: Does cyproconazole induce voriconazole resistance in <i>Aspergillus fumigatus</i> isolates?. <i>Current Medical Mycology</i> , 2020, 6, 14-19.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran. <i>Mycopathologia</i> , 2020, 185, 1077-1084.	1.3	30
38	Molecular epidemiology and antifungal susceptibility profiles of clinical <i>Cryptococcus neoformans</i> / <i>Cryptococcus gattii</i> species complex. <i>Journal of Medical Microbiology</i> , 2020, 69, 72-81.	0.7	13
39	Highly Concentrated Multifunctional Silver Nanoparticle Fabrication through Green Reduction of Silver Ions in Terms of Mechanics and Therapeutic Potentials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 19, 2140-2153.	0.9	4
40	1282. Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates <i>in vitro</i> Activity Against Members of the <i>Fusarium oxysporum</i> and <i>Fusarium solani</i> Species Complexes. <i>Open Forum Infectious Diseases</i> , 2020, 7, S656-S656.	0.4	0
41	In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging <i>Candida</i> Species. <i>Mycopathologia</i> , 2019, 184, 607-613.	1.3	24
42	In vitro activities of 15 antifungal drugs against a large collection of clinical isolates of <i>Microsporium canis</i> . <i>Mycoses</i> , 2019, 62, 1069-1078.	1.8	23
43	Potential Fifth Clade of <i>Candida auris</i> , Iran, 2018. <i>Emerging Infectious Diseases</i> , 2019, 25, 1780-1781.	2.0	257
44	Antifungal Resistance Testing and Implications for Management. <i>Current Fungal Infection Reports</i> , 2019, 13, 274-283.	0.9	13
45	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e405-e421.	4.6	970
46	Unequivocal identification of an underestimated opportunistic yeast species, <i>Cyberlindnera fabianii</i> , and its close relatives using a dual-function PCR and literature review of published cases. <i>Medical Mycology</i> , 2019, 57, 833-840.	0.3	11
47	Novel Point Mutations in <i>cyp51A</i> and <i>cyp51B</i> Genes Associated with Itraconazole and Posaconazole Resistance in <i>Aspergillus clavatus</i> Isolates. <i>Microbial Drug Resistance</i> , 2019, 25, 652-662.	0.9	20
48	Airway colonisation by <i>Candida</i> and <i>Aspergillus</i> species in Iranian cystic fibrosis patients. <i>Mycoses</i> , 2019, 62, 434-440.	1.8	12
49	Comparison of 21-Plex PCR and API 20C AUX, MALDI-TOF MS, and rDNA Sequencing for a Wide Range of Clinically Isolated Yeast Species: Improved Identification by Combining 21-Plex PCR and API 20C AUX as an Alternative Strategy for Developing Countries. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 21.	1.8	28
50	A simple and low cost tetra-primer ARMS-PCR method for detection triazole-resistant <i>Aspergillus fumigatus</i> . <i>Molecular Biology Reports</i> , 2019, 46, 4537-4543.	1.0	7
51	New potent antifungal triazole alcohols containing N-benzylpiperazine carbodithioate moiety: Synthesis, in vitro evaluation and in silico study. <i>Bioorganic Chemistry</i> , 2019, 90, 103060.	2.0	20
52	In vitro activity of nine antifungal agents against a global collection of <i>Hortaea werneckii</i> isolates, the agent of tinea nigra. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 95-98.	1.1	7
53	Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2019, 393, 1958-1972.	6.3	3,062
54	Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 376-393.	4.9	359

#	ARTICLE	IF	CITATIONS
55	<i>Candida auris</i> otomycosis in Iran and review of recent literature. Mycoses, 2019, 62, 101-105.	1.8	75
56	An unusual case of gastrointestinal basidiobolomycosis mimicking colon cancer; literature and review. Journal De Mycologie Medicale, 2019, 29, 75-79.	0.7	21
57	Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine,the, 2019, 7, 69-89.	5.2	326
58	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	4.9	1,064
59	Epidemiology of <i>Aspergillus</i> species causing keratitis in Mexico. Mycoses, 2019, 62, 144-151.	1.8	25
60	YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagnostic Microbiology and Infectious Disease, 2019, 93, 112-119.	0.8	42
61	Cellular apoptosis: An alternative mechanism of action for caspofungin against Candida glabrata. Current Medical Mycology, 2019, 5, 9-15.	0.8	5
62	Indifferent effect of nonsteroidal anti-inflammatory drugs (NSAIDs) combined with fluconazole against multidrug-resistant Candida auris. Current Medical Mycology, 2019, 5, 26-30.	0.8	6
63	Candidemia due to Candida guilliermondii in an immuno-compromised infant: a case report and review of literature. Current Medical Mycology, 2019, 5, 32-36.	0.8	10
64	Comparative virulence of <i>Candida auris</i> with <i>Candida haemulonii</i>, <i>Candida glabrata</i> and <i>Candida albicans</i> in a murine model. Mycoses, 2018, 61, 377-382.	1.8	98
65	Pesticide behavior in paddy fields and development of azole-resistant Aspergillus fumigatus : Should we be concerned?. Journal De Mycologie Medicale, 2018, 28, 59-64.	0.7	32
66	Discovery of benzylthio analogs of fluconazole as potent antifungal agents. Future Medicinal Chemistry, 2018, 10, 987-1002.	1.1	18
67	Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995â€“2015. Lancet, The, 2018, 391, 1799-1829.	6.3	127
68	Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016â€“40. Lancet, The, 2018, 391, 1783-1798.	6.3	172
69	Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infectious Diseases, 2018, 18, 24.	1.3	86
70	Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients. Microbial Pathogenesis, 2018, 115, 353-357.	1.3	9
71	In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions. Diagnostic Microbiology and Infectious Disease, 2018, 91, 266-268.	0.8	8
72	Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	27

#	ARTICLE	IF	CITATIONS
73	<i>In Vitro</i> Antifungal Activity of Novel Triazole Eflinaconazole and Five Comparators against Dermatophyte Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	48
74	Use of cell surface protein typing for genotyping of azole-resistant and susceptible <i>Aspergillus fumigatus</i> isolates in Iran. <i>Mycoses</i> , 2018, 61, 143-147.	1.8	8
75	Cerebral phaeohyphomycosis due to <i>Rhinochlamydia mackenziei</i> in Persian Gulf region: A case and review. <i>Mycoses</i> , 2018, 61, 261-265.	1.8	17
76	In vitro antifungal activity of amphotericin B and 11 comparators against <i>Aspergillus terreus</i> species complex. <i>Mycoses</i> , 2018, 61, 134-142.	1.8	29
77	Evaluation of PCR-reverse line blot hybridization assay for simultaneous identification of medically important saprophytic fungi. <i>Journal De Mycologie Medicale</i> , 2018, 28, 173-179.	0.7	0
78	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	6.3	716
79	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	6.3	4,989
80	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
81	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
82	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
83	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
84	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
85	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1329-1349.	4.6	144
86	Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2018, 17, 1061-1082.	4.9	221
87	Eighty Years of Mycopathologia: A Retrospective Analysis of Progress Made in Understanding Human and Animal Fungal Pathogens. <i>Mycopathologia</i> , 2018, 183, 859-877.	1.3	21
88	Emerging <i>Candida</i> species isolated from renal transplant recipients: Species distribution and susceptibility profiles. <i>Microbial Pathogenesis</i> , 2018, 125, 240-245.	1.3	37
89	Molecular epidemiology of environmental <i>Cryptococcus</i> species isolates based on amplified fragment length polymorphism. <i>Journal De Mycologie Medicale</i> , 2018, 28, 599-605.	0.7	16
90	Frequency and Geographic Distribution of CARD9 Mutations in Patients With Severe Fungal Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 2434.	1.5	78

#	ARTICLE	IF	CITATIONS
91	Low <i>In Vitro</i> Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	18
92	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
93	Azole-Resistance in <i>Aspergillus terreus</i> and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	1.5	66
94	Low-Cost Tetraplex PCR for the Global Spreading Multi-Drug Resistant Fungus, <i>Candida auris</i> and Its Phylogenetic Relatives. Frontiers in Microbiology, 2018, 9, 1119.	1.5	29
95	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	6.3	2,005
96	Severe Disseminated Phaeohyphomycosis in a Patient with Inherited CARD9 Deficiency. Archives of Clinical Infectious Diseases, 2018, 13, .	0.1	7
97	Molecular Identification of Clinically Common and Uncommon Yeast Species. Jundishapur Journal of Microbiology, 2018, In Press, .	0.2	2
98	A Review of Esophagitis Due to <i>Candida</i> Species in Human Immunodeficiency Virus (HIV) Infected Patients. International Journal of Enteric Pathogens, 2018, 6, 84-88.	0.2	0
99	Consistent high prevalence of <i>Exophiala dermatitidis</i> , a neurotropic opportunist, on railway sleepers. Journal De Mycologie Medicale, 2017, 27, 180-187.	0.7	16
100	Successful treatment with caspofungin of candiduria in a child with Wilms tumor; review of literature. Journal De Mycologie Medicale, 2017, 27, 261-265.	0.7	19
101	A prospective international <i>Aspergillus terreus</i> survey: an EFISC, ISHAM and ECMM joint study. Clinical Microbiology and Infection, 2017, 23, 776.e1-776.e5.	2.8	42
102	Coexistence of aspergilloma and pulmonary hydatid cyst in an immunocompetent individual. Journal De Mycologie Medicale, 2017, 27, 396-399.	0.7	6
103	Epidemiological and mycological characteristics of candidemia in Iran: A systematic review and meta-analysis. Journal De Mycologie Medicale, 2017, 27, 146-152.	0.7	60
104	<i>In Vitro</i> Activities of Luliconazole, Lanconazole, and Efinaconazole Compared with Those of Five Antifungal Drugs against Melanized Fungi and Relatives. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	24
105	<i>In Vitro</i> Interactions of Echinocandins with Triazoles against Multidrug-Resistant <i>Candida auris</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	75
106	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the <i>Cryptococcus</i> Genus. MSphere, 2017, 2, .	1.3	124
107	Expression Patterns of ABC Transporter Genes in Fluconazole-Resistant <i>Candida glabrata</i> . Mycopathologia, 2017, 182, 273-284.	1.3	14
108	<i>In Vitro</i> Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of <i>Candida</i> Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	22

#	ARTICLE	IF	CITATIONS
109	Whole Genome-Based Amplified Fragment Length Polymorphism Analysis Reveals Genetic Diversity in <i>Candida africana</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 556.	1.5	19
110	Antifungal susceptibility testing of <i>Candida</i> species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates. <i>BMC Infectious Diseases</i> , 2017, 17, 727.	1.3	37
111	Microsatellite Genotyping of <i>Candida parapsilosis</i> Clinical Isolates. <i>Current Medical Mycology</i> , 2017, 3, 15-20.	0.8	6
112	Multicenter Identification and Antifungal Susceptibility Patterns of <i>Candida</i> Species Isolated from Clinical Samples. <i>Jundishapur Journal of Microbiology</i> , 2017, 10, .	0.2	2
113	Caspofungin-Non-Susceptible Isolated from Onychomycosis in Iran. <i>Iranian Journal of Public Health</i> , 2017, 46, 235-241.	0.3	5
114	Genetic and Morphological Diversity of the Genus <i>Penicillium</i> From Mazandaran and Tehran Provinces, Iran. <i>Jundishapur Journal of Microbiology</i> , 2016, 9, e28280.	0.2	9
115	Genotyping of clinical and environmental <i>Aspergillus flavus</i> isolates from Iran using microsatellites. <i>Mycoses</i> , 2016, 59, 220-225.	1.8	12
116	In Vitro Activities of Five Antifungal Drugs Against Opportunistic Agents of <i>Aspergillus Nigri</i> Complex. <i>Mycopathologia</i> , 2016, 181, 235-240.	1.3	33
117	<i>In vitro</i> activity of new azoles luliconazole and lanconazole compared with ten other antifungal drugs against clinical dermatophyte isolates: Table 1.. <i>Medical Mycology</i> , 2016, 54, 757-763.	0.3	66
118	Amino acid substitutions in Erg11p of azole-resistant <i>Candida glabrata</i> : Possible effective substitutions and homology modelling. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 5, 42-46.	0.9	16
119	Potent Activities of Novel Imidazoles Lanconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible <i>Aspergillus fumigatus</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6916-6919.	1.4	39
120	Mucormycosis in Iran: a systematic review. <i>Mycoses</i> , 2016, 59, 402-415.	1.8	76
121	Coinfection of Pulmonary Hydatid Cyst and Aspergilloma: Case Report and Systematic Review. <i>Mycopathologia</i> , 2016, 181, 255-265.	1.3	15
122	In vitro activities of five antifungal agents against 199 clinical and environmental isolates of <i>Aspergillus flavus</i> , an opportunistic fungal pathogen. <i>Journal De Mycologie Medicale</i> , 2016, 26, 116-121.	0.7	17
123	Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran. <i>Mycopathologia</i> , 2016, 181, 89-95.	1.3	67
124	High prevalence of clinical and environmental triazole-resistant <i>Aspergillus fumigatus</i> in Iran: is it a challenging issue?. <i>Journal of Medical Microbiology</i> , 2016, 65, 468-475.	0.7	60
125	Is human dectin-1 Y238X gene polymorphism related to susceptibility to recurrent vulvovaginal candidiasis?. <i>Current Medical Mycology</i> , 2016, 2, 15-19.	0.8	18
126	Disseminated Nocardiosis in an Immunocompetent Individual Infected with <i>Nocardia brasiliensis</i> , an Opportunistic Agent. <i>Archives of Clinical Infectious Diseases</i> , 2016, 12, .	0.1	1

#	ARTICLE	IF	CITATIONS
127	Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections. Jundishapur Journal of Microbiology, 2016, 9, e34151.	0.2	9
128	In Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen. Jundishapur Journal of Microbiology, 2016, 9, e36638.	0.2	12
129	In Vitro Antifungal Susceptibility Profiles of Candida albicans Complex Isolated from Patients with Respiratory Infections. Acta Medica Iranica, 2016, 54, 376-81.	0.8	8
130	<i>cyp51A</i> gene silencing using <i>RNA</i> interference in azole-resistant <i>Aspergillus fumigatus</i> . Mycoses, 2015, 58, 699-706.	1.8	15
131	Cryptococcal meningitis due to <i>Cryptococcus neoformans</i> genotype <i>AFLP1/VNI</i> in Iran: a review of the literature. Mycoses, 2015, 58, 689-693.	1.8	16
132	Use of Restriction Fragment Length Polymorphism to Rapidly Identify Dermatophyte Species Related to Dermatophytosis. Jundishapur Journal of Microbiology, 2015, 8, e17296.	0.2	23
133	Global Spread of Human Chromoblastomycosis Is Driven by Recombinant <i>Cladophialophora carrionii</i> and Predominantly Clonal <i>Fonsecaea</i> Species. PLoS Neglected Tropical Diseases, 2015, 9, e0004004.	1.3	21
134	First Autochthonous Coinfected Anthrax in an Immunocompetent Patient. Case Reports in Medicine, 2015, 2015, 1-5.	0.3	1
135	First fatal cerebral phaeoohyphomycosis due to <i>Rhinocladiella mackenziei</i> in Iran, based on ITS rDNA. Journal De Mycologie Medicale, 2015, 25, 81-86.	0.7	15
136	Synthesis and biological evaluation of fluconazole analogs with triazole-modified scaffold as potent antifungal agents. Bioorganic and Medicinal Chemistry, 2015, 23, 1481-1491.	1.4	39
137	Multilocus sequence typing of <i>Candida albicans</i> isolates from a burn intensive care unit in Iran. Journal of Medical Microbiology, 2015, 64, 248-253.	0.7	32
138	Molecular Characterization of Highly Susceptible <i>Candida africana</i> from Vulvovaginal Candidiasis. Mycopathologia, 2015, 180, 317-323.	1.3	44
139	<i>In vitro</i> susceptibility patterns of clinically important <i>Trichophyton</i> and <i>Epidermophyton</i> species against nine antifungal drugs. Mycoses, 2015, 58, 303-307.	1.8	64
140	<i>In Vitro</i> Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of <i>Phaeoacremonium</i> . Antimicrobial Agents and Chemotherapy, 2015, 59, 7818-7822.	1.4	9
141	Novel triazole alcohol antifungals derived from fluconazole: design, synthesis, and biological activity. Molecular Diversity, 2015, 19, 15-27.	2.1	31
142	Use of restriction fragment length polymorphism to identify <i>Candida</i> species, related to onychomycosis. Advanced Biomedical Research, 2015, 4, 95.	0.2	19
143	Use of Padlock Probes and Rolling Circle Amplification (RCA) for Rapid Identification of <i>Trichophyton</i> Species, Related to Human and Animal Disorder. Jundishapur Journal of Microbiology, 2015, 8, e19107.	0.2	4
144	In vitro activity of econazole in comparison with three common antifungal agents against clinical <i>Candida</i> strains isolated from superficial infections. Current Medical Mycology, 2015, 1, 7-12.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Molecular Diversity of <i>Candida albicans</i> Isolated from Immunocompromised Patients, Based on MLST Method. Iranian Journal of Public Health, 2015, 44, 1262-9.	0.3	6
146	Imidazolylchromanones containing non-benzylic oxime ethers: Synthesis and molecular modeling study of new azole antifungals selective against <i>Cryptococcus gattii</i> . European Journal of Medicinal Chemistry, 2014, 76, 264-273.	2.6	25
147	<i>Cladophialophora abundans</i> , a novel species of Chaetothyriales isolated from the natural environment. Mycological Progress, 2014, 13, 381-391.	0.5	21
148	A reappraisal of orders and families within the subclass Chaetothyriomycetidae (Eurotiomycetes). Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	0.5	62
149	Use of Rolling Circle Amplification to Rapidly Identify Species of <i>Cladophialophora</i> Potentially Causing Human Infection. Mycopathologia, 2013, 175, 431-438.	1.3	19
150	Chromoblastomycosis due to <i>Fonsecaea pedrosoi</i> and <i>F. monophora</i> in Cuba. Mycopathologia, 2013, 175, 439-444.	1.3	20
151	<i>Veronaea botryosa</i> : Molecular Identification with Amplified Fragment Length Polymorphism (AFLP) and In vitro Antifungal Susceptibility. Mycopathologia, 2013, 175, 505-513.	1.3	22
152	Endocarditis due to a co-infection of <i>Candida albicans</i> and <i>Candida tropicalis</i> in a drug abuser. Journal of Medical Microbiology, 2013, 62, 1763-1767.	0.7	41
153	In Vitro Antifungal Susceptibility of <i>Cladophialophora carrionii</i> , an Agent of Human Chromoblastomycosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1974-1977.	1.4	26
154	Severe Disseminated Phaeohyphomycosis in an Immunocompetent Patient Caused by <i>Veronaea botryosa</i> . Mycopathologia, 2013, 175, 497-503.	1.3	44
155	Molecular characterisation and pathogenicity of <i>Phaeoacremonium</i> spp. associated with esca disease of grapevine in Northern Iran. Archives of Phytopathology and Plant Protection, 2013, 46, 375-388.	0.6	20
156	An unusual case of eumycetoma caused by <i>Exophiala jeanselmei</i> after a sea urchin injury. Mycoses, 2013, 56, 491-494.	1.8	9
157	Environmental study of azole-resistant <i>Aspergillus fumigatus</i> with TR ₃₄ /L98H mutations in the <i>cyp51A</i> gene in Iran. Mycoses, 2013, 56, 659-663.	1.8	98
158	First case of disseminated phaeohyphomycosis in an immunocompetent individual due to <i>Alternaria malorum</i> . Medical Mycology, 2013, 51, 196-202.	0.3	26
159	Multiple subcutaneous cysts due to <i>Exophiala spinifera</i> in an immunocompetent patient. Medical Mycology, 2012, 50, 207-213.	0.3	20
160	Molecular Tools in Medical Mycology; Where We Are!. Jundishapur Journal of Microbiology, 2012, 6, 1-3.	0.2	10
161	Epidemiology and molecular characterization of <i>Cryptococcus neoformans</i> isolated from pigeon excreta in Mazandaran province, northern Iran. Journal De Mycologie Medicale, 2012, 22, 160-166.	0.7	12
162	Fatal Cerebral Phaeohyphomycosis in an Immunocompetent Individual Due to <i>Thielavia subthermophila</i> . Journal of Clinical Microbiology, 2011, 49, 2336-2341.	1.8	15

#	ARTICLE	IF	CITATIONS
163	Cladophialophora psammophila, a novel species of Chaetothyriales with a potential use in the bioremediation of volatile aromatic hydrocarbons. Fungal Biology, 2011, 115, 1019-1029.	1.1	73
164	Exophiala sideris, a novel black yeast isolated from environments polluted with toxic alkyl benzenes and arsenic. Fungal Biology, 2011, 115, 1030-1037.	1.1	72
165	Waterborne <i>Exophiala</i> species causing disease in cold-blooded animals. Persoonia: Molecular Phylogeny and Evolution of Fungi, 2011, 27, 46-72.	1.6	191
166	Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Medical Mycology, 2011, 49, 819-824.	0.3	41
167	Melanization of a Meristematic Mutant of Fonsecaea monophora Increases Tolerance to Stress Factors While no Effects on Antifungal Susceptibility. Mycopathologia, 2011, 172, 373-380.	1.3	25
168	<i>In Vitro</i> Activities of Eight Antifungal Drugs against 55 Clinical Isolates of <i>Fonsecaea</i> spp. Antimicrobial Agents and Chemotherapy, 2010, 54, 1636-1638.	1.4	57
169	In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection. Journal of Antimicrobial Chemotherapy, 2010, 65, 175-177.	1.3	26
170	First Autochthonous Case of <i>Rhinocladiella mackenziei</i> Cerebral Abscess Outside the Middle East. Journal of Clinical Microbiology, 2010, 48, 646-649.	1.8	36
171	The clinical spectrum of <i>Exophiala jeanselmei</i> , with a case report and <i>in vitro</i> antifungal susceptibility of the species. Medical Mycology, 2010, 48, 318-327.	0.3	43
172	Use of Amplified Fragment Length Polymorphism To Identify 42 <i>Cladophialophora</i> Strains Related to Cerebral Phaeohyphomycosis with In Vitro Antifungal Susceptibility. Journal of Clinical Microbiology, 2010, 48, 2350-2356.	1.8	55
173	<i>Rhinocladiella aquaspersa</i> , proven agent of verrucous skin infection and a novel type of chromoblastomycosis. Medical Mycology, 2010, 48, 696-703.	0.3	55
174	Subcutaneous phaeohyphomycotic cyst caused by <i>Pyrenochaeta romeroi</i> . Medical Mycology, 2010, 48, 763-768.	0.3	37
175	Successful treatment of chromoblastomycosis of 36 years duration caused by <i>Fonsecaea monophora</i> . Medical Mycology, 2010, 48, 390-393.	0.3	35
176	Successful treatment of chromoblastomycosis of 36 years duration caused by Fonsecaea monophora. Medical Mycology, 2010, 48, 1-4.	0.3	24
177	The clinical spectrum of Exophiala jeanselmei, with a case report and in vitro antifungal susceptibility of the species. Medical Mycology, 2010, 48, 1-10.	0.3	37
178	<i>Cladophialophora saturnica</i> sp. nov., a new opportunistic species of <i>Chaetothyriales</i> revealed using molecular data. Medical Mycology, 2009, 47, 51-62.	0.3	59
179	In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species. Journal of Antimicrobial Chemotherapy, 2009, 63, 1295-1297.	1.3	24
180	Genetic diversity and species delimitation in the opportunistic genus Fonsecaea. Medical Mycology, 2009, 47, 17-25.	0.3	80

#	ARTICLE	IF	CITATIONS
181	Biodiversity of the genus <i>Cladophialophora</i> . <i>Studies in Mycology</i> , 2008, 61, 175-191.	4.5	172
182	<i>Tinea nigra</i> by <i>Hortaea werneckii</i> , a report of 22 cases from Mexico. <i>Studies in Mycology</i> , 2008, 61, 77-82.	4.5	75
183	Seroepidemiological Study for Toxocariasis among Children in Zanjan-Northwest of Iran. <i>Pakistan Journal of Biological Sciences</i> , 2008, 11, 1844-1847.	0.2	27
184	Molecular analysis and pathogenicity of the <i>Cladophialophora carrionii</i> complex, with the description of a novel species. <i>Studies in Mycology</i> , 2007, 58, 219-234.	4.5	114
185	Fungal Contamination in Indoor Swimming Pools in Zanjan-Iran 2005. <i>Pakistan Journal of Biological Sciences</i> , 2006, 9, 2524-2527.	0.2	4
186	In vitro activity of 23 antifungal drugs against 54 clinical and environmental <i>Aspergillus oryzae</i> isolates. <i>Mycoses</i> , 0, , .	1.8	3